- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04453800
The Efficacy and Safety of Sofadil for Injection in the Treatment of Acute Ischemic Stroke
June 30, 2020 updated by: Peking University Third Hospital
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Sofadil for Injection in the Treatment of Acute Ischemic Stroke
To evaluate the efficacy and safety of sofadil injection in the treatment of acute ischemic stroke
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The limited therapeutic time window for neuroprotection has prevented all clinical trials using NMDA receptor antagonists in subjects with ischemic stroke from showing efficacy.
In animal models of ischemic stroke, antioxidants showed a longer neuroprotective time window than NMDA receptor antagonists, and also showed therapeutic potential in clinical trials in subjects with ischemic stroke.
Sophadil showed good neuroprotective effects against NMDA and free-radical mediated cell death, NR2B-selectivity, moderate NMDA receptor antagonism, and effective cellular osmotic antioxidant activity even at nanoscale molarity.
Non-clinical and phase I human clinical studies have shown that Sofadil is helpful in treating ischemic stroke subjects with better efficacy and therapeutic time windows.
So we designed the clinical trial to evaluate the efficacy and safety of sofadil injection in the treatment of acute ischemic stroke
Study Type
Interventional
Enrollment (Actual)
236
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Dongsheng Fan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The target population is 35-75 years old, regardless of gender;
- within 6h of onset, ischemic stroke of the internal carotid artery system;
- Neurological deficits, including limb weakness, with acute brain injury (NIHSS score) (4-22 points), or NIHSS item 5 upper limb or 6 lower limb score ≥2 points;
- Be able to initiate study treatment within 6 hours of onset of symptoms or within 6 hours of last appearing normal (6 hours after sleep in subjects with ischemic stroke who developed during sleep) and complete post-onset CT examination prior to study treatment;
- Obtain the informed consent signed by the subject or the subject's legal representative;
- MRS score before onset was 0~1;
- Patients with no history of myocardial infarction within 3 months;
- Centerless, liver, kidney and lung dysfunction;
- No hemorrhagic disease within 3 months;
- No blood system diseases.
Exclusion Criteria:
- Any contraindications to CT or MRI (such as metal implants such as pacemaker, claustrophobia, etc
- Stroke caused by posterior circulation ischemia, or TIA;
- Acute intracranial hemorrhage, intracranial tumor, subarachnoid hemorrhage, encephalitis or other non-acute ischemic stroke (onset less than 6 hours), intracranial arteriovenous malformations;
- Patients who plan to undergo endovascular treatment, such as mechanical thrombectomy, stenting or arteriovenous bridging, within 6 hours after onset;
- Pregnant or lactating women. Note: The blood pregnancy test for fertile women before randomization must be negative and appropriate contraception should be used at least 3 weeks before randomization until 7 days after study drug infusion
- A pre-existing medical, neurological or psychiatric disorder that confuses neurological, functional or imaging assessments, such as persistent injury from previous ischemic stroke;
- Patients with malignant tumors or other critical diseases;
- Having a history of epilepsy or having epileptiform symptoms at the onset of stroke;
- Previous history of intracranial hemorrhage;
- Patients with previous hypotension or blood pressure of less than 90/60mmhg measured for 3 consecutive times;
- Patients with severe injuries and surgical history within 3 months;
- People with consciousness disorder can be defined as "NIHSS score Ia ≥2 points";
- Bradycardia with complete atrioventricular block;
- According to the New York heart association (NYHA) grade of cardiac function, cardiac function rating above Ⅱ level, a history of congestive heart failure (CHF).
- Patients with primary liver and kidney diseases, AST or ALT twice as high as the normal upper limit, serum creatinine >2.0 mg/dL or >176.8 mol/L;
- Where the INR is greater than 1.7 or where an oral anticoagulant is currently used, except aspirin, clopidogrel, subcutaneous heparin or Wartamine;
- Patients with bleeding tendency diseases (such as hemophilia), and partial thromboplastin time (PTT) is more than 3 times of the normal upper limit;
- Having a current drug or alcohol problem or experience;
- Has the experience of allergic reaction to the research drugs or drugs with similar chemical structure;
- Participated in other clinical trials or clinical study participants within 3 months before the start of this study;
- The researcher considered it inappropriate to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A :low dose sofadil
500mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
|
500mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Other Names:
|
EXPERIMENTAL: Group B: Medium dose group
750mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
|
750mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Other Names:
1500mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Other Names:
|
EXPERIMENTAL: Group C: high dose group
1500mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
|
750mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Other Names:
1500mg Intravenous infusion of sofadil starting at 500mg was 500ml,followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Other Names:
|
PLACEBO_COMPARATOR: Group D: placebo group
Saline was administered intravenously
|
Saline was administered intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with a NIHSS score
Time Frame: 14±2 days of treatment
|
Proportion of subjects with a NIHSS score of 0 ~ 1 or 4 or more points less than baseline NIHSS at 14±2 days of treatment
|
14±2 days of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in NIHSS score
Time Frame: at 14±2, 30±2, and 90±7 days after treatment compared to baseline
|
Changes in NIHSS score at 14±2, 30±2, and 90±7 days after treatment compared to baseline
|
at 14±2, 30±2, and 90±7 days after treatment compared to baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2016
Primary Completion (ACTUAL)
January 1, 2018
Study Completion (ACTUAL)
January 1, 2018
Study Registration Dates
First Submitted
June 28, 2020
First Submitted That Met QC Criteria
June 30, 2020
First Posted (ACTUAL)
July 1, 2020
Study Record Updates
Last Update Posted (ACTUAL)
July 1, 2020
Last Update Submitted That Met QC Criteria
June 30, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUTH2017013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance